Skip to main content
SpringerLink
Log in

Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Sera of ten healthy controls and of 15 patients with myelodysplastic syndromes (MDS) were investigated for soluble interleukin-2 receptor (sIL-2R) with a cell-free enzyme-linked immunosorbent assay (ELISA). The patients with MDS underwent treatment with IL-3: eigth patients at dose levels of 250 and 500 Μg/m2 s.c. daily for 15 days, and seven patients at the dose levels of 60 and 125 Μg/m2 s.c. three times per week for 12 weeks. None of the patients had reported infectious episodes or been under treatment with cytotoxic drugs and/or cytokines within the preceding 2 months. sIL-2R levels were elevated in MDS patients compared with healthy controls (p<0.001). sIL-2R increased in the high-dose treatment group from 504±68 U/ml to 731±199 U/ml (p<0.025). The increased sIL2R expression in MDS could be a primary event due to involvement of lymphocytes in the malignant clone or due to a secondary alteration of the cytokine network caused by chronic neutropenia. A down-regulation of the immune response caused by neutralization of free IL-2 by sIL-2R during IL-3 therapy seems possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ayanlar-Batuman O, Shevitz J, Traub U, Murphy S, Sajewski D (1987) Lymphocyte interleukin-2 production and responsiveness are altered in patients with primary myelodysplastic syndromes. Blood 70:494–500

    PubMed  Google Scholar 

  2. Baumann M, Milson T, Patrick C, Libnoch J, Keller R (1986) Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol 22:17–26

    PubMed  Google Scholar 

  3. Bennett JM, Catovsky D, Flandrin G, Daniel MT, Galton DAG, Gralnick H, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199

    PubMed  Google Scholar 

  4. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD (1988) Human granulocyte-monocyte colony-stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 71:672–676

    PubMed  Google Scholar 

  5. Espinoza-Delgado I, Ortaldo JR, Winkler-Pickett R, Sugumura K, Varesio L, Longo DL (1990) Expression and role of p75 interleukin-2 receptor on human monocytes. J Exp Med 171:1821–1825

    PubMed  Google Scholar 

  6. Ganser A, Hoelzer D (1992) Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:607–618

    PubMed  Google Scholar 

  7. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D (1990) Effect of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666–676

    PubMed  Google Scholar 

  8. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M, Hermann F, Becher R, Höffken K, Büchner T, Klausmann M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462

    PubMed  Google Scholar 

  9. Ganser A, Janssen JWG, Ottmann OG, Seipelt G, Eder M, Becher R, Lindemann A, Herrmann F, Schulz G, Mertelsmann R, Hoelzer D, Bartram CR (1991) In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia 5:487–492

    PubMed  Google Scholar 

  10. Ganser A, Ottmann OG, Seipelt G, Lindemann A, Hess U, Geissler GH, Maurer A, Frisch J, Schulz G, Mertelsmann R, Hoelzer D (1993) Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 7:696–701

    PubMed  Google Scholar 

  11. Gazzola MV, Collins NH, Tafuri A, Keefer CA (1992) Recombinant interleukin-3 induces interleukin-2 receptor expression on early myeloid cells in normal human bone marrow. Exp Hematol 20:201–208

    PubMed  Google Scholar 

  12. Hancock WW, Pleau ME, Kobzik L (1988) Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin. J Immunol 140:3021–3025

    PubMed  Google Scholar 

  13. Herrmann F, Cannistra SA, Levine H, Griffin JD (1985) Expression of interleukin-2 receptors and binding of interleukin- 2 by gamma interferon-induced leukemic and normal monocytic cells. J Exp Med 162:1111–1116

    PubMed  Google Scholar 

  14. Ho A, Haas R, Wulf G, Knauf W, Ehrhardt R, Heilig B, Körbling M, Schulz G, Hunstein W (1990) Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 75:203–212

    PubMed  Google Scholar 

  15. Janssen JWG, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H, Heimpel H, Kubanek B, Kleihauer E, Mufti GJ, Bartram CR (1990) Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73:248–254

    Google Scholar 

  16. Kerndrup G, Meyer K, Ellegard J, Kokland P (1984) Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leukemia Res 8:239–247

    Google Scholar 

  17. Kurzrock R, Talpaz M, Estrov Z, Rosenblum G, Gutterman JU (1991) Phase-I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250

    PubMed  Google Scholar 

  18. Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R (1991) Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 9:2120–2127

    PubMed  Google Scholar 

  19. Martin S, Baldock S, Ghomein A, Child J (1983) Defective neutrophil function and microbicidal mechanism in the myelodysplastic disorders. J Clin Pathol 36:1120–1125

    PubMed  Google Scholar 

  20. Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K (1989) Differential expression of the IL-2 receptor subunits p55 and p75 on various populations of primary peripheral blood mononuclear cells. J Immunol 143:3448–3553

    PubMed  Google Scholar 

  21. Rubin L, Kurman C, Fritz M, Biddison W, Boutin B, Yarchoan R, Nelson D (1985) Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177

    PubMed  Google Scholar 

  22. Symeonidis A, Kourakli A, Katevas P, Perraki M, Tiniakou M, Matsouka P, Georgoulias V, Zoumbos N (1991) Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 47:277–281

    PubMed  Google Scholar 

  23. Tsukamoto N, Morita K, Maehara T, Okamoto K, Karasawa M, Omine M, Naruse T (1993) Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83:589–594

    PubMed  Google Scholar 

  24. Zwierzina H, Sepp N, Ringler E, Schmalzl F (1989) Delayed maturation of skin window macrophages in myelodysplastic syndromes. Leukemia Res 6:433–435

    Google Scholar 

  25. Zwierzina H, Herold M, Schöllenberger S, Geissler D, Schmalzl F (1991) Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Br J Haematol 79:438–443

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Hämatologie, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe-Universität, Theodor Stern Kai 7, D-60590, Frankfurt, Germany

    G. Seipelt, A. Ganser, H. Duranceyk, A. Maurer, O. G. Ottmann & D. Hoelzer

Authors
  1. G. Seipelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Duranceyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. G. Ottmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Hoelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seipelt, G., Ganser, A., Duranceyk, H. et al. Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Ann Hematol 68, 167–170 (1994). https://doi.org/10.1007/BF01834361

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01834361

Key words

Search

Navigation